Cart
sales@molnova.com
STM2457
CAS No. 2499663-01-1
STM2457( —— )
Catalog No. M24139 CAS No. 2499663-01-1
STM2457 is a first-in-class, highly potent, selective and orally active inhibitor of METTL3 . It can be used for the research of acute myeloid leukaemia (AML).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 194 | In Stock |
|
| 10MG | 314 | In Stock |
|
| 25MG | 521 | In Stock |
|
| 50MG | 745 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSTM2457
-
NoteResearch use only, not for human use.
-
Brief DescriptionSTM2457 is a first-in-class, highly potent, selective and orally active inhibitor of METTL3 . It can be used for the research of acute myeloid leukaemia (AML).
-
DescriptionSTM2457 is a first-in-class, highly potent, selective and orally active inhibitor of METTL3 . It can be used for the research of acute myeloid leukaemia (AML).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorMETTL3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2499663-01-1
-
Formula Weight444.53
-
Molecular FormulaC25H28N6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:125 mg/mL (281.20 mM; Need ultrasonic)
-
SMILESO=C(C(N=C1N2C=CC=C1)=CC2=O)NCC3=CN4C=C(CNCC5CCCCC5)C=CC4=N3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Wesley Peter Blackaby, et al. Mettl3 inhibitory compounds. WO2020201773A1.
molnova catalog
related products
-
2-Methoxystypandrone
2-Methoxystypandrone displays an immunomodulatory effect in a cellular model, it blocks inflammatory responses by impairing NF-?oB signaling to limit the inflammation and oxidative stress for preservation of BBB integrity.
-
Guaiacylglycerol 8-O...
The herbs of Juniperus formosana.
-
FEN1 Inhibitor C2
FEN1-IN-4 is an inhibitor of human flap endonuclease-1 (hFEN1)FEN1 Inhibitor C2 inhibition selectively impairs proliferation of colon cancer cells deficient in Cdc4 and Mre11a, both frequently mutated in colorectal cancers.?
